Skip to main content

Our Outputs

Our Outputs

Some of our recent papers.

Veal GJ, Tweddle DA, Visser J, Errington J, Buck H, Marange J, Moss J, Joseph S, Mulla H. Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: a randomised, crossover clinical trialCancers 2021, 13(8), 1868 (1-13).

Barnett S, Kong J, Makin G, Veal GJ. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United KingdomBritish Journal of Clinical Pharmacology 2021, 87(2), 256-262.

Gowland C, Berry P, Errington J, Jeffrey P, Bennett G, Godfrey L, Pittman M, Niewiarowski A, Symeonides SN, Veal GJ. Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I studyBioanalysis 2021, 13(2), 101-113.

Gionfriddo I, Brunetti B, Mezzasoma F, Milano F, Cardinali V, Ranieri R, Venanzi A, Pierangeli S, Vetro C, Spinozzi G, Dorillo E, Wu H, Ciurnelli R, Griffin MJ, Jennings CE, Tiavvi E, Sportoletti E, Falzetti F, de The H, Veal GJ, Martelli MP, Falini B. Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemiaLeukemia 2021. In Press.

Barnett S, Errington J, Sludden J, Jamieson D, Poinsignon V, Paci A, Veal GJ. Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population.  Pharmaceuticals 2021, 14(3), 272 (1-11).

Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020 583:807-812.

Faivre-Finn C, Brown S, Ryan A, Greystoke A; CONCORDE Investigators. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24. PMID: 32107107.

Roberts, E, Mogg, JAW, Barnfield, M, Veal, GJ. Investigating current practices in renal function measurement and carboplatin dosing in children with cancer – a UK perspective. Ped Hem Oncol 2020 37: 235-244

Merugu S, Chen L, Gavens E, Gabra H, Brougham M, Makin G, Ng A, Murphy D, Gabriel AS, Robinson ML, Wright JH, Burchill SA, Humphreys A, Bown N, Jamieson D, Tweddle DA. Detection of circulating and disseminated neuroblastoma cells using the Imagestream Imaging Flow Cytometer for use as predictive and pharmacodynamic biomarkers. Clinical Cancer Research 2020 26:122-134

Doan M, Case M, Masic D, Hennig H, McQuin C, Caicedo J, Singh S, Goodman A, Wolkenhauer O, Summers HD, Jamieson D, van Delft FW, Filby A, Carpenter AE, Rees P, Irving J. Label‐Free Leukemia Monitoring by Computer Vision. Cytometry A 2020 97:407-414

Hellmann F, Völler S, Krischke M. Jamieson D, Andre N, Bisogno G, Boddy A, Hemple G. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the “European Paediatric Oncology Off-patents Medicines Consortium” (EPOC) Trial. Eur J Drug Metab Pharmacokinet 2020 45:413–422

Yogev, O, Almeida, GS, Barker, KT, George, SL, Kwok, C, Campbell, J, Zarowiecki, M, Kleftogiannis, D, Smith, LM, Hallsworth, A, Berry, P, Möcklinghoff, T, Webber, HT, Danielson, LS, Buttery, B, Calton, EA, da Costa, BM, Jamin, Y, Lise, S, Veal, GJ, Sebire, N, Robinson, SP, Anderson, J, Chesler, L. In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis. Cancer Res 2019 79: 5382-5393

Jackson, RK, Liebich, M, Berry, P, Errington, J, Liu, J, Parker, C, Moppett, J, Samarasinghe, S, Hough, R, Rowntree, C, Goulden, NJ, Vora, A, Kearns, PR, Saha, V, Hempel, G, Irving, JAE, Veal, GJ. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia – a report from the UKALL 2011 trial. Eur J Cancer 2019 120: 75-85

Smith, SJ, Tyler, BM, Gould, T, Veal, GJ, Gorelick, N, Rowlinson, J, Serra, R, Ritchie, A, Berry, P, Otto, A, Choi, J, Skuli, N, Estevez-Cebrero, M, Shakesheff, KM, Brem, H, Grundy, RG, Rahman, R. Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste. Clin Cancer Res 2019 25: 5094-5106

Hawley, J, Veal, GJ, Errington, J, McDonald, LG, Tweddle, DA. The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma associated spinal cord compression. Ped Blood Cancer 2019 e27825 1-3

Uitrakul, S, Hutton, C, Veal, GJ, Jamieson, D. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells. Eur J Clin Invest 2019 49: e13115 1-7

Lee, CM, Zane, NR, Veal, G, Thakker, DR. Physiologically-based pharmacokinetic models for adults and children reveal a role of intracellular tubulin binding in vincristine disposition. CPT Pharmacometrics Syst Pharmacol 2019 8: 759-768

Veal, GJ, Amankwatia, EB, Paludetto, M-N, Möcklinghoff, T, Thomson, F, André, N, Ciccolini, J, Chatelut, E. Pharmacodynamic therapeutic drug monitoring for cancer: challenges, advances and future opportunities. Ther Drug Monit 2019 41: 142-159

Adamson, PC, Veal, GJ, Womer, RB, Meany, HJ, Bernhardt, MB, Frazier, AL, Balis, FM. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine based estimates of renal function. Ped Blood Cancer 2019 66: e27672 1-8

Matheson, EC, Thomas, H, Case, M, Blair, H, Jackson, RK, Masic, D, Veal, G, Halsey, C, Newell, DR, Vormoor, J, Irving, JAE. Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood ALL through upregulation of BIM. Haematologica 2019 104: 1804-1811

Danilenko, M, Hodgson, K, Stones, R, Husain, A, Zangarini, M, Veal, G, Rajan, N. Diverse assays from a single skin punch biopsy to assess topical drug intervention. Br J Dermatology 2019 180: 937-938

Chen, L, Pastorino, F, Berry, P, Bonner, J, Kirk, C, Wood, KM, Thomas, HD, Zhao, Y, Daga, A, Veal, GJ, Lunec, J, Newell, DR, Ponzoni, M, Tweddle, DA. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Int J Cancer 2019 144: 3146-3159

Duong, JK, Veal, GJ, Nath, CE, Shaw, PJ, Errington, J, Ladenstein, R, Boddy, AV. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: A re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Br J Clin Pharmacol 2019 85: 136-146

Brock, PR, Maibach, R, Childs, M, Rajput, K, Roebuck, D, Sullivan, MJ, Laithier, V, Ronghe, M, dall'Igna, P, Hiyama, E, Brichard, B, Skeen, J, Mateos, ME, Capra, M, Rangaswami, AA, Veal, GJ, Brugières, L, Perilongo, G, Czauderna, P, Morland, B, Neuwelt, EA. Sodium thiosulfate for protection from cisplatin-induced hearing loss. New Engl J Med 2018 378: 2376-2385

Martinez-Soria, N, McKenzie, L, Draper, J, Ptasinska, A, Issa, H, Potluri, S, Blair, HJ, Pickin, A, Isa, A, Tirtakusuma, R, Coleman, D, Pal, D, Nakjang, S, Suyin Chin, P, Assi, S, Forster, V, Reza, M, Law, E, Berry, P, Mueller, D, Elder, A, Veal, GJ, Cockerill, PN, Wichmann, C, Vormoor, J, Lacaud, G, Bonifer, C, Heidenreich, O. The oncogenic transcription factor RUNX1/ETO corrupts cell cycle regulation to drive leukemic transformation. Cancer Cell 2018 34: 626-642

Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018 2:1157-1169.

Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? British Journal of Cancer 2018 118:248-257

Danilenko, M, Stamp, E, Stocken, DD, Husain, A, Zangarini, M, Cranston, A, Stones, R, Sinclair, N, Hodgson, K, Bowett, SA, Roblin, D, Traversa, S, Plummer, R, Veal, G, Langtry, JAA, Ashworth, A, Burn, J, Rajan, N. Efficacy of targeting tropomyosin receptor kinase in cutaneous CYLD defective tumours (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib. JAMA Dermatology 2018 154: 913-921

Thomas, F, Veal, GJ, El Balkhi, S, Lafont, T, Picard, N, Brugières, L, Chatelut, E, Piguet, C. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemother Pharmacol 2018 82: 361-365

White-Koning, M, Osborne, C, Paci, A, Boddy, AVB, Chatelut, E, Veal, GJ. Investigating the potential impact of dose-banding for systemic anti-cancer therapy (SACT) in the paediatric setting based on pharmacokinetic evidence. Eur J Cancer 2018 91: 56-67

Kim, HY, Veal, GJ, Zhou, F, Boddy, AV. The Role of Solute Carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients. Eur J Clin Pharmacol 2018 74: 1575-1584

Fischer-Huchzermeyer S, Chikobava L, Stahn V, Zangarini M, Berry P, Veal GJ, Senner V, Mautner VF, Harder A. Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. BMC Research Notes 2018 11:520

Seddon, B, Strauss, SJ, Whelan, J, Leahy, M, Woll, PJ, Cowie, F, Rothermundt, C, Wood, Z, Benson, C, Ali, N, Marples, M, Veal, GJ, Jamieson, D, Küver, K, Tirabosco, R, Forsyth, S, Nash, S, Dehbi, H-M, Beare, S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017 18: 1397-1410

Veal, GJ, Malik, S, Lupo, M, MacFarlane, S, Lepola, P, Costello, M, Ceci, A, Boué, C, Lecour, L, Otto, A, Rastegari, M, Berry, P. Investigating the roles and training of paediatric research nurses working across Europe - a questionnaire-based survey. BMJ Paediatrics Open 2017 1: e00170 1-7

Zangarini, M, Berry, P, Sludden, J, Raynaud, FI, Banerji, U, Jones, P, Edwards, E, Veal, GJ. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 (CHK1) inhibitor SRA737 in human plasma. Bioanalysis 2017 9: 1001-1010

Vormoor, B, Veal, GJ, Griffin, MJ, Boddy, AV, Irving, J, Minto, L, Case, M, Banerji, U, Swales, KE, Tall, JR, Moore, AS, Toguchi, M, Acton, G, Dyer, K, Schwab, C, Harrison, CJ, Grainger, JD, Lancaster, D, Kearns, P, Hargrave, D, Vormoor, J. A Phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukaemia: challenges to run early phase clinical trials for children with leukaemia. Ped Blood Cancer 2017 64: e26351 1-4

Jamieson D, Sunter N, Muro S, Pouché L, Cresti N, Lee J, Sludden J, Griffin MJ, Allan JM, Verrill MW, Boddy AV. Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. Eur J Cancer 2017 71:15-24.

Ribeiro R, Pal D, Jamieson D, Rankin K, Benning M, Dalgarno K, Ferreira A. Temporary Single Cell Coating for Bioprocessing via a Cationic Polymer. ACS Applied Materials & Interfaces 2017 9:12967-12974.